Dianthus Therapeutics, Inc.
DNTH
Rank in Stocks
#3956
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Share Price
$74.96
Market Cap
$4.19B
Change (1 day)
3.98%
Change (1 year)
110.27%
Country
US
Trade Dianthus Therapeutics, Inc. (DNTH)
Category
Healthcare
Stock split history for Dianthus Therapeutics, Inc. (DNTH)
Dianthus Therapeutics, Inc. stock (symbol: DNTH) underwent a total of 1 stock splits.
The most recent stock split occurred on Sep 12, 2023.
One DNTH share bought prior to Sep 12, 2023 would equal to 0.0625 DNTH shares today.
The most recent stock split occurred on Sep 12, 2023.
One DNTH share bought prior to Sep 12, 2023 would equal to 0.0625 DNTH shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2023-09-12 | 1:16 | x0.0625 | x0.0625 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
